MRNA vs. NVAX

In the year-to-date period, MRNA achieves a -61.43% return, which is significantly lower than NVAX's 79.79% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Moderna, Inc. (MRNA) and Novavax, Inc. (NVAX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current MRNA Sharpe Ratio is -0.90, which is lower than the NVAX Sharpe Ratio of 0.47. The chart below compares the historical Sharpe Ratios of MRNA and NVAX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither MRNA nor NVAX has paid dividends to shareholders.

The maximum MRNA drawdown since its inception was -92.39%, smaller than the maximum NVAX drawdown of -98.82%. Use the drawdown chart below to compare losses from any high point for MRNA and NVAX. For additional features, visit the drawdowns tool.

Moderna, Inc. (MRNA) has a higher volatility of 19.57% compared to Novavax, Inc. (NVAX) at 17.24%. This indicates that MRNA's price experiences larger fluctuations and is considered to be riskier than NVAX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Moderna, Inc. and Novavax, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.